References
- Ali, A.A., Weinstein, R.S., Stewart, S.A., Parfitt, A.M., Manolagas, S.C., and Jilka, R.L. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 146, 1226-1235. https://doi.org/10.1210/en.2004-0735
- Backesjo, C.M., Li, Y., Lindgren, U., and Haldosen, L.A. (2006). Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner Res. 21, 993-1002. https://doi.org/10.1359/jbmr.060415
- Blakytny, R., Spraul, M., and Jude, E.B. (2011). Review: The diabetic bone: a cellular and molecular perspective. Int. J. Low Extrem Wounds. 10, 16-32. https://doi.org/10.1177/1534734611400256
- Borra, M.T., Smith, B.C., and Denu, J.M. (2005). Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195. https://doi.org/10.1074/jbc.M501250200
- Chang, F., Jaber, L.A., Berlie, H.D., and O'Connell, M.B. (2007). Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41, 973-983. https://doi.org/10.1345/aph.1K013
- Choi, S.E., and Kemper, J.K. (2013). Regulation of SIRT1 by microRNAs. Mol. Cells 36, 385-392. https://doi.org/10.1007/s10059-013-0297-1
- Cohen-Kfir, E., Artsi, H., Levin, A., Abramowitz, E., Bajayo, A., Gurt, I., Zhong, L., D'Urso, A., Toiber, D., Mostoslavsky, R., et al. (2011). Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152, 4514-4524. https://doi.org/10.1210/en.2011-1128
- Desvergne, B., and Wahli, W. (1999). Peroxisome proliferatoractivated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688.
- Feng, Z., Deng, H., Du, J., Chen, D., Jiang, R., and Liang, X. (2011). Lentiviral-mediated RNAi targeting p38MAPK ameliorates high glucose-induced apoptosis in osteoblast MC3T3-E1 cell line. Indian J. Exp. Biol. 49, 94-104.
- Finkel, T., Deng, C.X., and Mostoslavsky, R. (2009). Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591. https://doi.org/10.1038/nature08197
- Gong, K., Qu, B., Liao, D., Liu, D., Wang, C., Zhou, J., and Pan, X. (2016). MiR-132 regulates osteogenic differentiation via downregulating Sirtuin1 in a peroxisome proliferator-activated receptor beta/delta-dependent manner. Biochem. Biophys. Res. Commun. 478, 260-267. https://doi.org/10.1016/j.bbrc.2016.07.057
- Haigis, M.C., and Sinclair, D.A. (2010). Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253-295. https://doi.org/10.1146/annurev.pathol.4.110807.092250
- Issemann, I., and Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650. https://doi.org/10.1038/347645a0
- Lecka-Czernik, B. (2010). PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr. Osteoporos. Rep. 8, 84-90. https://doi.org/10.1007/s11914-010-0016-1
- Mayoral, R., Osborn, O., McNelis, J., Johnson, A.M., Oh, D.Y., Izquierdo, C.L., Chung, H., Li, P., Traves, P.G., Bandyopadhyay, G., et al. (2015). Adipocyte SIRT1 knockout promotes PPARgamma activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol. Metab. 4, 378-391. https://doi.org/10.1016/j.molmet.2015.02.007
- Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., and Guarente, L. (2004). Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429, 771-776. https://doi.org/10.1038/nature02583
- Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M., Zhao, Y., Gu, W., Farmer, S.R., et al. (2012). Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma. Cell 150, 620-632. https://doi.org/10.1016/j.cell.2012.06.027
- Qu, B., Ma, Y., Yan, M., Gong, K., Liang, F., Deng, S., Jiang, K., Ma, Z., and Pan, X. (2016). Sirtuin1 promotes osteogenic differentiation through downregulation of peroxisome proliferator-activated receptor gamma in MC3T3-E1 cells. Biochem. Biophys.Res. Commun. 478, 439-445. https://doi.org/10.1016/j.bbrc.2016.06.154
- Raisz, L.G. (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325. https://doi.org/10.1172/JCI27071
- Rakel, A., Sheehy, O., Rahme, E., and LeLorier, J. (2008). Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 34, 193-205. https://doi.org/10.1016/j.diabet.2007.10.008
- Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puigserver, P. (2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434, 113-118. https://doi.org/10.1038/nature03354
- Schwartz, A.V. (2016). Efficacy of osteoporosis therapies in diabetic patients. Calcif. Tissue Int. 100, 165-173.
- Stunes, A.K., Westbroek, I., Gustafsson, B.I., Fossmark, R., Waarsing, J.H., Eriksen, E.F., Petzold, C., Reseland, J.E., and Syversen, U. (2011). The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr. Disord. 11, 11. https://doi.org/10.1186/1472-6823-11-11
- Syversen, U., Stunes, A.K., Gustafsson, B.I., Obrant, K.J., Nordsletten, L., Berge, R., Thommesen, L., and Reseland, J.E. (2009). Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr. Disord. 9, 10. https://doi.org/10.1186/1472-6823-9-10
- Takano, M., Otsuka, F., Matsumoto, Y., Inagaki, K., Takeda, M., Nakamura, E., Tsukamoto, N., Miyoshi, T., Sada, K.E., and Makino, H. (2012). Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-alpha. Mol. Cell Endocrinol. 348, 224-232. https://doi.org/10.1016/j.mce.2011.08.027
- Wang, Y., Liang, Y., and Vanhoutte, P.M. (2011). SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett. 585, 986-994. https://doi.org/10.1016/j.febslet.2010.11.047
- Yao, H., and Rahman, I. (2012). Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem. Pharmacol. 84, 1332-1339. https://doi.org/10.1016/j.bcp.2012.06.031
- Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C.R., Granner, D.K., et al. (2001). Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131-138. https://doi.org/10.1038/35093050
- You, L., Gu, W., Chen, L., Pan, L., Chen, J., and Peng, Y. (2014). MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. Int. J. Clin. Exp. Pathol. 7, 7249-7261.
- Zhang, W.L., Meng, H.Z., Yang, R.F., Yang, M.W., Sun, G.H., Liu, J.H., Shi, P.X., Liu, F., and Yang, B. (2016). Melatonin suppresses autophagy in type 2 diabetic osteoporosis. Oncotarget 7, 52179-52194. https://doi.org/10.18632/oncotarget.10538
Cited by
- Sirt1/Foxo Axis Plays a Crucial Role in the Mechanisms of Therapeutic Effects of Erzhi Pill in Ovariectomized Rats vol.2018, pp.1741-4288, 2018, https://doi.org/10.1155/2018/9210490
- Current understanding and future perspectives of the roles of sirtuins in the reprogramming and differentiation of pluripotent stem cells vol.243, pp.6, 2017, https://doi.org/10.1177/1535370218759636
- MiR-155 inhibition alleviates suppression of osteoblastic differentiation by high glucose and free fatty acids in human bone marrow stromal cells by upregulating SIRT1 vol.472, pp.4, 2017, https://doi.org/10.1007/s00424-020-02372-7
- Peroxisome Proliferator-Activated Receptors and Caloric Restriction—Common Pathways Affecting Metabolism, Health, and Longevity vol.9, pp.7, 2017, https://doi.org/10.3390/cells9071708
- Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm vol.12, pp.11, 2020, https://doi.org/10.3390/nu12113476
- When Activator and Inhibitor of PPARα Do the Same: Consequence for Differentiation of Human Intestinal Cells vol.9, pp.9, 2017, https://doi.org/10.3390/biomedicines9091255